Neuroscientist awarded grant to study serotonin-based modulation to treat seizures
October 16, 2024
October 16, 2024
BLACKSBURG, Virginia, Oct. 16 -- Virginia Tech issued the following news:
Dravet syndrome, a rare form of epilepsy that affects one in 15,000 people, is fatal to one in five with the disorder. It is most often caused by a gene mutation that overexcites the brain.
Fenfluramine, a drug approved to treat Dravet syndrome, represents a significant advance for these patients. It reduces seizures by increasing serotonin which regulates mood, appetite, movement, and sensation. . . .
Dravet syndrome, a rare form of epilepsy that affects one in 15,000 people, is fatal to one in five with the disorder. It is most often caused by a gene mutation that overexcites the brain.
Fenfluramine, a drug approved to treat Dravet syndrome, represents a significant advance for these patients. It reduces seizures by increasing serotonin which regulates mood, appetite, movement, and sensation. . . .